CDK6 and Mobius syndrome: In a computational-based approach to predict miR-124 target genes, Pierson et al. discovered and validated cyclin dependent kinase 6 (CDK6) that was identified as an adverse prognostic marker in MB and solute carrier family 16, member 1(SLC16A1) that may represent a novel therapeutic target for treatment of malignant MBs [89,90].